Cardiovascular risks of androgen deprivation therapy for prostate cancer

被引：1
|
作者：
Miller, K. [1 ]
机构：
[1] Klin & Hsch Ambulanz Urol, Charitepl 1, D-10117 Berlin, Germany
来源：
UROLOGE | 2016年 / 55卷 / 05期
关键词：
Prostate cancer; Androgen deprivation therapy; Cardio vascular events; GnRH antagonists; LHRH agonists; MEN; DISEASE; ASSOCIATION; SUPPRESSION; MORBIDITY; MORTALITY;
D O I：
10.1007/s00120-015-0021-1
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Androgen deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer. It has increasingly been used in other stages of the disease as well. Besides well-known side effects caused by the lack of testosterone (impotency, osteoporosis, fatigue, loss of muscle mass), an increase of cardiovascular (CV) morbidity and mortality has recently been discussed in association with ADT. Cardiovascular side effects cannot be sufficiently explained by low testosterone levels. This review gives an overview of the recent literature, interprets the results, and offers clinical consequences.
引用
收藏
页码：627 / 631
页数：5
相关论文
共 50 条
  • [1] Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
    Corona, Giovanni
    Filippi, Sandra
    Bianchi, Nicola
    Dicuio, Mauro
    Rastrelli, Giulia
    Concetti, Sergio
    Sforza, Alessandra
    Maggi, Mario
    [J]. WORLD JOURNAL OF MENS HEALTH, 2021, 39 (03): : 429 - 443
  • [2] Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer
    Atalar, Kerem
    Rajan, Prabhakar
    [J]. NATURE REVIEWS UROLOGY, 2023, 20 (01) : 3 - 4
  • [3] Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer
    Nambudiri, Vinod E.
    Keating, Nancy L.
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (04) : 531 - 537
  • [4] Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer
    Kerem Atalar
    Prabhakar Rajan
    [J]. Nature Reviews Urology, 2023, 20 : 3 - 4
  • [5] Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients
    Muniyan, Sakthivel
    Xi, Lei
    Datta, Kaustubh
    Das, Anindita
    Teply, Benjamin A.
    Batra, Surinder K.
    Kukreja, Rakesh C.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1874 (01):
  • [6] Cardiovascular Risks of Androgen Deprivation Therapy
    Ribeiro, Adriano Freitas
    Camara, Cesar
    Segre, Carlos Alexandre
    Srougi, Miguel
    Serrano, Carlos V., Jr.
    [J]. ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2010, 95 (03) : 412 - 415
  • [7] Androgen Deprivation Therapy for Prostate Cancer and Cardiovascular Death
    Blankfield, Robert P.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (12): : 1252 - 1252
  • [8] Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer
    Gupta D.
    Salmane C.
    Slovin S.
    Steingart R.M.
    [J]. Current Treatment Options in Cardiovascular Medicine, 2017, 19 (8)
  • [9] Androgen deprivation therapy and cardiovascular risk in prostate cancer
    DE Nunzio, Cosimo
    Fiori, Cristian
    Fusco, Ferdinando
    Gregori, Andrea
    Pagliarulo, Vincenzo
    Alongi, Filippo
    [J]. MINERVA UROLOGY AND NEPHROLOGY, 2022, 74 (05): : 508 - 517
  • [10] Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer
    Megha Agarwal
    Timothy Canan
    Greg Glover
    Nidhi Thareja
    Andre Akhondi
    Joshua Rosenberg
    [J]. Current Oncology Reports, 2019, 21
12345